Atorvastatin restores arsenic-induced vascular dysfunction in rats: Modulation of nitric oxide signaling and inflammatory mediators

Toxicology and Applied Pharmacology

Volumn 280, Issue 1, 2014, Pages 107-116

  Kesavan, Manickam ^a   Sarath, Thengumpallil Sasindran ^a   Kannan, Kandasamy ^a   Suresh, Subramaniyam ^a   Gupta, Priyanka ^a   Vijayakaran, Karunakaran ^a   Sankar, Palanisamy ^a   Kurade, Nitin Pandurang ^a   Mishra, Santosh Kumar ^a   Sarkar, Souvendra Nath ^a  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

Author keywords

Arsenic; Atorvastatin; Inflammatory mediators; Nitric oxide signaling; Rat; Vascular dysfunction

Indexed keywords

ACUTE PHASE PROTEIN; ARSENITE SODIUM; ATORVASTATIN; C REACTIVE PROTEIN; DRINKING WATER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; VASCULAR CELL ADHESION MOLECULE 1; ACETYLCHOLINE; ARSENIC; AUTACOID; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ABDOMINAL AORTA; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FOAM CELL; GENE EXPRESSION; HISTOPATHOLOGY; ISOLATED ORGAN; ISOLATION PROCEDURE; MALE; MEDIATOR; MONONUCLEAR CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THORACIC AORTA; UPREGULATION; VASCULAR DISEASE; VASCULAR RING; CARDIOVASCULAR RISK; INFLAMMATION; PROTEIN PHOSPHORYLATION; RISK REDUCTION; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; VASCULAR ENDOTHELIUM; WISTAR RAT;

ANIMALS; AORTA, THORACIC; ARSENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; MALE; NITRIC OXIDE; ORGAN CULTURE TECHNIQUES; PYRROLES; RANDOM ALLOCATION; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84906518435     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.07.008     Document Type: Article

References (68)

1. Amarenco P., Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009, 8:453-463.
2. Argos M., Kalra T., Rathouz P.J., Chen Y., Pierce B., Parvez F., Islam T., Ahmed A., Rakibuz-Zaman M., Hasan R., Sarwar G., Slavkovich V., Geen A.V., Graziano J., Ahsan H. Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet 2010, 376:252-258.
3. Aung P.P., Maxwell H., Jepson R.G. Lipid-lowering for peripheral arterial diseases of the lower limb. Cochrane Database Syst. Rev. 2007, 4:CD000123.
4. Bersot T.P. Drug therapy for hypercholesterolemia and dyslipidemia. Goodman and Gilman's The Pharmacological Basis of Therapeutics 2011, 877-908. The Mc Grew Hill Company. L.L. Brunton, B.A. Chabner, B.C. Knollmann (Eds.).
5. Biswas D., Sen G., Sarkar A., Biswas T. Atorvastatin acts synergistically with N-acetyl cysteine to provide therapeutic advantage against Fas-activated erythrocyte apoptosis during chronic arsenic exposure in rats. Toxicol. Appl. Pharmacol 2010, 10.1016/j.taap.2010.10.002.
6. Blake G.J., Ridker P.M. Novel clinical markers of vascular wall inflammation. Circ. Res. 2001, 89:763-771.
7. Caliman I.F., Lamas A.Z., Dalpiaz P.L.M., Medeiros A.R.S., Abreu G.R., Figueiredo S.G., Gusmão L.N., Andrade T.U., Bissoli N.S. Endothelial relaxation mechanisms and oxidative stress are restored by atorvastatin therapy in ovariectomized rats. PLoS One 2013, 8:e80892.
8. Chen J., Kuhlencordt P.J., Astern J., Gyurko R., Huang P.L. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation 2001, 104:2391-2394.
9. Chen C.J., Wang S.L., Chiou J.M., Tseng C.H., Chiou H.Y., Hsueh Y.M., Chen S.Y., Wu M.M., Lai M.S. Arsenic and diabetes and hypertension in human populations: a review. Toxicol. Appl. Pharmacol. 2007, 222:298-304.
10. Cheng T.J., Chuu J.J., Chang C.Y., Tsai W.C., Chen K.J., Guo H.R. Atherosclerosis induced by arsenic in drinking water in rats through altering lipid metabolism. Toxicol. Appl. Pharmacol. 2011, 256:146-153.
11. Csanaky I., Nemeti B., Gregus Z. Dose-dependent biotransformation of arsenite in rats - not S-adenosylmethionine depletion impairs arsenic methylation at high dose. Toxicology 2003, 183:77-91.
12. Dimmeler S., Fleming I., Fisslthaler B., Herman C., Busse R., Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
13. Fulton D., Gratton J.-P., Sessa W.C. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough?. J. Pharmacol. Exp. Ther. 2001, 299:818-824.
14. Ca channels. FASEB J. 2004, 18:1382-1391.
15. Guha Mazumder D., Dasgupta U.B. Chronic arsenic toxicity: studies in West Bengal, India. Kaohsiung J. Med. Sci. 2011, 27:360-370.
16. Gurr J.R., Yih L.H., Samikkannu T., Bau D.T., Lin S.Y., Jan K.Y. Nitric oxide production by arsenite. Mutat. Res. 2003, 533:173-182.
17. Huang P.L., Huang Z., Mashimo H., Bloch K.D., Moskowitz M.A., Bevan J.A., Fishman M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995, 377:239-242.
18. Janssen-Heininger Y.M., Poynter M.E., Baeuerle P.A. Recent advances towards understanding redox mechanisms in the activation of nuclear factor κB. Free Radic. Biol. Med. 2000, 28:1317-1327.
19. Jiang J., Ashekuzzaman S.M., Jiang A., Sharifuzzaman S.M., Chowdhury S.R. Arsenic contaminated groundwater and its treatment options in Bangladesh. Int. J. Environ. Res. Public Health 2013, 10:18-46.
20. Jindal S., Singh M., Balakumar P. Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int. J. Cardiol. 2008, 128:283-291.
21. 1-adrenoceptor mRNA expression. Shock 2011, 36:76-82.
22. Kasper H.U., Schmidt A., Roessner A. Expression of the adhesion molecules ICAM, VCAM, and ELAM in the arteriosclerotic plaque. Gen. Diagn. Pathol. 1996, 141:289-294.
23. Kaur T., Goel R., Balakumar P. Effect of rosiglitazone in sodium arsenite induced experimental vascular endothelial dysfunction. Arch. Pharm. Res. 2010, 33:611-618.
24. Kawashima S., Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2004, 24:998-1005.
25. Kleemann R., Verschuren L., de Rooji B., Lindeman J., de Matt M.M., Szalai A.J., Princen H.M.G., Kooistra T. Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004, 103:4188-4194.
26. Kumagai Y., Pi J. Molecular basis for arsenic-induced alteration in nitric oxide production and oxidative stress: implication of endothelial dysfunction. Toxicol. Appl. Pharmacol. 2004, 198:450-457.
27. Lee M.Y., Jung B.I., Chung S.M., Bae O.N., Lee J.Y. Arsenic-induced dysfunction in relaxation of blood vessels. Environ. Health. Perspect. 2003, 111:513-517.
28. Li H., Forstermann U. Prevention of atherosclerosis by interference with the vascular nitric oxide system. Curr. Pharm. Des. 2009, 15:3133-3145.
29. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005, 45:89-118.
30. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 29(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
31. Majhi C.R., Khan S., Leo M.D.M., Manimaran A., Sankar P., Sarkar S.N. Effects of acetaminophen on reactive oxygen species and nitric oxide redox signaling in kidney of arsenic-exposed rats. Food Chem. Toxicol. 2011, 49:974-982.
32. Matthews J.R., Botting C.H., Panico M., Morris H.R., Hay R.T. Inhibition of NF-κB DNA binding by nitric oxide. Nucleic Acids Res. 1996, 24:2236-2242.
33. Niu X.F., Smith C.W., Kubes P. Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ. Res. 1994, 74:1133-1140.
34. Nohria A., Prsic A., Liu P.Y., Okamoto R., Creager M.A., Selwyn A., Liao J.K., Ganz P. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 2008, 205:517-521.
35. Paffen E., deMaat M.P.M. C-reactive protein in atherosclerosis: a causal factor?. Cardiovasc. Res. 2006, 71:30-39.
36. Papayianni A., Alexopoulos E., Giamalis P., Gionanlis L., Belechri A.M., Koukoudis P., Memmos D. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol. Dial. Transplant. 2002, 17:435-441.
37. Pi J., Horiguchi S., Sun Y., Nikaido M., Shimojo N., Hayashi T., Yamauchi H., Itoh K., Yamamoto M., Sun G., Waalkes M.P., Kumagai Y. A potential mechanism for the impairment of nitric oxide formation caused by prolonged oral exposure to arsenate in rabbits. Free Radic. Biol. Med. 2003, 35:102-113.
38. Prabu S.M., Muthumani M. Silibinin ameliorates arsenic induced nephrotoxicity by abrogation of oxidative stress, inflammation and apoptosis in rats. Mol. Biol. Rep. 2012, 39:11201-11216.
39. Rahaman S., Sinha A.C., Pati R., Mukhopadhyay D. Arsenic contamination: a potential hazard to the affected areas of West Bengal, India. Environ. Geochem. Health 2013, 35:119-132.
40. Rang H.P., Dale M.M., Ritter J.M., Flower R.J., Henderson G. Nitric oxide. Rang and Dale's Pharmacology 2012, 237-245. Elsevier, (Churchill Livingstone).
41. Rott D., Zhu J., Zhou Y.F., Burnett M.S., Zaalles-Ganley A., Epstein S.E. IL-6 is produced by spenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells: a new mechanistic paradigm for infection-induced atherogenesis. Atherosclerosis 2003, 170:223-228.
42. Roy D., Das T.K., Vaswani S. Arsenic: its extent of pollution and toxicosis: an animal perspective. Vet. World 2013, 6:53-58.
43. Savoia C., Schiffrin E.L. Inflammation in hypertension. Curr. Opin. Nephrol. Hypertens. 2006, 15:152-158.
44. Scumpia P.O., Sarcia P.J., Demarco V.G., Stevens B.R., Skimming J.W. Hypothermia attenuates iNOS, CAT-1, CAT-2 and nitric oxide expression in lungs of endotoxemic rats. Am. J. Physiol. 2002, 283:1231-1238.
45. Shao Q., Shen L.H., Hu L.H., Pu J., Jing Q., He B. Atorvastatin suppresses inflammatory response induced by oxLDL through inhibition of ERK phosphorylation, IκBα degradation, and COX-2 expression in murine macrophages. J. Cell. Biochem. 2012, 113:611-618.
46. Sharma B., Sharma P.M. Arsenic toxicity induced endothelial dysfunction and dementia: pharmacological interdiction by histone deacetylase and inducible nitric oxide synthase inhibitors. Toxicol. Appl. Pharmacol. 2013, 273:180-188.
47. Simeonova P.P., Hulderman T., Harki D., Luster M.I. Arsenic exposure accelerates atherogenesis in Apolipoprotein E(-/-) mice. Environ. Health Perspect. 2003, 111:1744-1748.
48. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
49. Srivastava S., Vladykovskaya E.N., Haberzettl P., Sithu S.D., D'Souza S.E., States J.C. Arsenic exacerbates atherosclerotic lesion formation and inflammation in ApoE-/- mice. Toxicol. Appl. Pharmacol. 2009, 241:90-100.
50. States J.C., Srivastava S., Chen Y., Barchowsky A. Arsenic and cardiovascular disease. Toxicol. Sci. 2009, 107:312-323.
51. Stea F., Bianchi F., Cori L., Sicari R. Cardiovascular effects of arsenic: clinical and epidemiological findings. Environ. Sci. Pollut. Res. 2014, 21:244-251.
52. Steed M.M., Tyagi N., Sen U., Schuschke D.A., Joshua I.G., Tyagi S.C. Functional consequences of the collagen/elastin switch in vascular remodeling in hyperhomocysteinemic wild-type eNOS-/- and iNOS-/- mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 299:L301-L311.
53. Styblo M., Del Razo L., Vega L., Germolec D.R., Le Cluyse E.L., Hamilton G.A., Reed W., Wang C., Cullen W.R., Thomas D.J. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol. 2000, 74:289-299.
54. Subramani J., Kathirvel K., Leo M.D., Kuntamallappanavar G., Singh T.U., Mishra S.K. Atorvastatin restores the impaired vascular endothelium-dependent relaxations mediated by nitric oxide and endothelium-derived hyperpolarizing factors but not hypotension in sepsis. J. Cardiovasc. Pharmacol. 2009, 54:526-534.
55. Sumi D. Biological effects of and responses to exposure to electrophilic environmental chemicals. J. Health Sci. 2008, 54:267-272.
56. Sun J., Druhan L.J., Zweier J.L. Reactive oxygen and nitrogen species regulate inducible nitric oxide synthase function shifting the balance of nitric oxide and superoxide production. Arch. Biochem. Biophys. 2010, 494:130-137.
57. Szmitko P.E., Wang C.H., Weisel R.D., de Almeida J.R., Anderson T.J., Verma S. New markers of inflammation and endothelial cell activation: part I. Circulation 2003, 108:1917-1923.
58. Tedder T.F., Steeber D.A., Chen A., Engel P. The selectins: vascular adhesion molecules. FASEB J. 1995, 9:866-873.
59. Tsou T., Tsai F., Hsieh Y., Li L., Yeh S.C., Chang L.W. Arsenite induces endothelial cytotoxicity by down-regulation of vascular endothelial nitric oxide synthase. Toxicol. Appl. Pharmacol. 2005, 208:277-284.
60. Verma S., Reddy K., Balakumar P. The defensive effect of benfotiamine in sodium arsenite induced experimental vascular endothelial dysfunction. Biol. Trace Elem. Res. 2010, 137:96-109.
61. Virdis A., Ghiadoni L., Giannarrelli C., Taddei S. Endothelial dysfunction and vascular disease in later life. Maturitas 2010, 67:20-24.
62. Wagner A.H., Schwabe O., Hecker M. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br. J. Pharmacol. 2002, 136:143-149.
63. v channel gene expression in rat distal pulmonary artery. Am. J. Physiol. 2005, 288:1049-1058.
64. Wayman N.S., Ellis B.L., Thiemermann C. Simvastatin reduces infarct size in a model of acute myocardial ischaemia and reperfusion in the rat. Med. Sci. Monit. 2003, 9:195-199.
65. Yang H.T., Chou H.J., Han B.C., Huang S.Y. Lifelong inorganic arsenic compounds consumption affected blood pressure in rats. Food Chem. Toxicol. 2007, 45:2479-2487.
66. Yeh E.T.H. CRP as a mediator of disease. Circulation 2004, 109. (II-11-II-14).
67. Zhang X., Recchia F.A., Bernstein R., Xu X., Nasjletti A., Hintze T.H. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure. J. Pharmacol. Exp. Ther. 1999, 288:742-751.
68. Zhou M.S., Schuman I.H., Jaimes E.A., Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-β and fibronectin with concomitant increase in nitric oxide bioavailability. Am. J. Physiol. Renal Physiol. 2008, 295:F53-F59.